Envoy Medical, Inc. (COCH)
NASDAQ: COCH · Real-Time Price · USD
0.7016
-0.0184 (-2.56%)
At close: Apr 16, 2026, 4:00 PM EDT
0.7156
+0.0140 (2.00%)
After-hours: Apr 16, 2026, 4:12 PM EDT
Company Description
Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum.
The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire.
It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants.
The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023.
Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Envoy Medical, Inc.
| Country | United States |
| Founded | 1995 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Brent Lucas |
Contact Details
Address: 4875 White Bear Parkway White Bear Lake, Minnesota 55110 United States | |
| Phone | 877 900 3277 |
| Website | envoymedical.com |
Stock Details
| Ticker Symbol | COCH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1840877 |
| CUSIP Number | 29415V109 |
| ISIN Number | US29415V1098 |
| Employer ID | 86-1369123 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Brent T. Lucas Esq. | Chief Executive Officer and Director |
| Robert M. Potashnick | Interim Chief Financial Officer and Principal Accounting Officer |
| Karin Simonson | Vice President, General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 13, 2026 | 10-K/A | [Amend] Annual report |
| Apr 2, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2026 | ARS | Filing |
| Apr 2, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 23, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 23, 2026 | 10-K | Annual Report |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13D/A | Filing |